UFP Technologies (UFPT) Stock: Buy, Sell, or Hold?
UFPT - UFP Technologies Inc
$294.99
-1.83 (-0.62%)
âŧ
5d:
-1.17%
30d:
+0.32%
90d:
+8.31%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 02, 2026
30d
Get Alerted When UFPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: UFPT is fairly priced but lacks strong directional signals. At 5.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: UFPT is fairly priced but lacks strong directional signals. At 5.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$369.25
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$229.27
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UFPT is currently trading at $294.99, which is considered slightly high relative to its 30-day fair value range of $279.79 to $299.52. From a valuation perspective, the stock is trading at a premium (Forward PE: 24.9) compared to its historical average (21.3). At these levels, the market is pricing in 5.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UFPT is in a strong uptrend. The price is approaching resistance at $301.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: UFPT scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $355.00 (+20.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UFPT is in a strong uptrend. The price is approaching resistance at $301.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: UFPT scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $355.00 (+20.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$279.79 -
$299.52
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.9%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.3% below Wall St target ($355.00)
- NEUTRAL: Trading at premium valuation - market expects 5.3% growth which is achievable
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$279.79 -
$299.52
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$273.00
Resistance Level
$301.25
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.85
Wall Street Target
$355.00
(+20.3%)
Revenue Growth (YoY)
15.1%
Earnings Growth (YoY)
21.3%
Profit Margin
11.5%
Valuation Premium vs History
+5.3% premium
PE vs Historical
24.9 vs 21.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.3%
(market-implied from PE analysis)
1-Year Target
$310.62
(+5%)
2-Year Target
$327.09
(+11%)
3-Year Target
$344.42
(+17%)
3-Yr Target (if PE normalizes)
(PE: 25â21)
PE COMPRESSION
$295.26
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.8, Growth: 11.8%)
$412.15
(+40%)
Base:
(SPY PE: 20.4, Growth: 11.8%)
$338.40
(+15%)
Bear:
(PE: 17.3, Growth: 11.8%)
$287.64
(-3%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 32.05 | Current EPS (TTM): $9.26
Bull Case
$418.62
(+42%)
Analyst growth 28.2%, PE expands to 35.3
Base Case
$380.56
(+29%)
Market implied 28.2%, PE stable at 32.1
Bear Case
$201.84
(-32%)
Severe decline -20.0%, PE contracts to 27.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 4:54 AM ET
Data refreshes hourly during market hours. Next update: 5:54 AM
Data refreshes hourly during market hours. Next update: 5:54 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UFPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 57 HOLD |
